We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.82B
AUM Growth
-$609M
Cap. Flow
-$347M
Cap. Flow %
-19.1%
Top 10 Hldgs %
52.59%
Holding
435
New
56
Increased
93
Reduced
114
Closed
122

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$9.22M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$7.3M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.22M
4
UTHR icon
United Therapeutics
UTHR
+$5.06M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$4.98M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$22.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.2M
3
VTRS icon
Viatris
VTRS
+$18.1M
4
PXD
Pioneer Natural Resource Co.
PXD
+$15M
5
EW icon
Edwards Lifesciences
EW
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 10.47%
2 Technology 0.45%
3 Consumer Staples 0.1%
4 Industrials 0.09%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REGN icon
351
Regeneron Pharmaceuticals
REGN
$73.1B
– –
-1,150
Closed -$535K
REGN icon
352
PUT
Regeneron Pharmaceuticals
REGN
$73.1B
– –
-53
Closed -$2.46M
SKY icon
353
Champion Homes
SKY
$4.47B
– –
-447,944
Closed -$3.45M
THC icon
354
Tenet Healthcare
THC
$22.3B
– –
-245,938
Closed -$8.07M
THC icon
355
PUT
Tenet Healthcare
THC
$22.3B
– –
-2,907
Closed -$10.7M
TLPH icon
356
CALL
Talphera
TLPH
$67M
– –
-9
Closed -$52K
TLPH icon
357
Talphera
TLPH
$67M
– –
-4,930
Closed -$301K
TLPH icon
358
PUT
Talphera
TLPH
$67M
– –
-9
Closed -$57K
TPST icon
359
Tempest Therapeutics
TPST
$14.1M
– –
-102
Closed -$3.36M
TPST icon
360
PUT
Tempest Therapeutics
TPST
$14.1M
– –
-1
Closed -$1.87M
VTRS icon
361
Viatris
VTRS
$20.9B
– –
-376,827
Closed -$18.1M
RDGT
362
Ridgetech Inc
RDGT
$917K
– –
-17
Closed -$1.12M
NVRO
363
DELISTED
NEVRO CORP.
NVRO
– –
-9,066
Closed -$485K
CDMO
364
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
– –
-1,558
Closed -$215K
SEEL
365
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– -$18K
SEEL
366
PUT
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– -$88K
BIOL
367
DELISTED
Biolase, Inc.
BIOL
– –
-23
Closed -$255K
PXD
368
DELISTED
Pioneer Natural Resource Co.
PXD
– –
-123,600
Closed -$15M
PXD
369
PUT
DELISTED
Pioneer Natural Resource Co.
PXD
– –
-1,236
Closed -$15M
BPTH
370
DELISTED
Bio-Path Holdings Inc
BPTH
– –
-4
Closed -$17K
INFI
371
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-30,000
Closed -$258K
INFI
372
PUT
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-300
Closed -$254K
NUVA
373
CALL
DELISTED
NuVasive, Inc.
NUVA
– –
-320
Closed -$1.54M
ACGN
374
DELISTED
Aceragen Inc
ACGN
– –
-1,014
Closed -$454K
ACGN
375
PUT
DELISTED
Aceragen Inc
ACGN
– –
-8
Closed -$372K
13 14
15
16 17

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2015 Portfolio in Review

As of Q4 2015, Sabby Management held 435 positions worth $1.82B, down 25% from $2.43B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $347M in Q4 2015, closing 122 positions and reducing 114 holdings. Its most notable exit was Biogen, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 13% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in Alkermes worth $10.5M.

  • Sabby Management's largest Q4 2015 buy was Alkermes: 131,671 shares worth $10.5M.
  • Sabby Management added most to Tobira Therapeutics, Inc. Common Stock in Q4 2015, an estimated $7.3M increase.
  • Sabby Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $11.6M.
  • Sabby Management fully exited Biogen in Q4 2015, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.82B portfolio in Q4 2015.
  • Sabby Management opened 56 new positions and closed 122 in Q4 2015.
  • Sabby Management's portfolio value fell 25% quarter-over-quarter to $1.82B.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.